Please login to the form below

Not currently logged in
Email:
Password:

Inlyta

This page shows the latest Inlyta news and features for those working in and with pharma, biotech and healthcare.

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

inhibitor Keytruda (pembrolizumab) from Merck &Co/MSD, including impressive survival data in combination with Pfizer’s Inlyta (axitinib) in the phase 3 KEYNOTE-426 trial reported at this year’s ESMO

Latest news

More from news
Approximately 7 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The therapy area is dominated by Merck’s Keytruda, BMS’Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it ... The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    Back then, the UK’ s cost-effectiveness watchdog NICE  deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower

  • Oncology drugs under AMNOG

    A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability. ... of benefit in one category for these patients was enough to send Inlyta to negotiations for pricing.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics